B cell receptor (BCR) complex (BCR)

The B cell receptor (BCR) complex is a critical component of the adaptive immune system, primarily responsible for recognizing specific antigens and initiating B cell activation and differentiation. It consists of a membrane-bound immunoglobulin molecule associated with a signaling heterodimer composed of CD79A and CD79B. Upon antigen binding, the BCR triggers a complex intracellular signaling cascade involving kinases such as SYK, PI3K, and BTK, which are essential for B cell survival and proliferation. In many B-cell malignancies, such as chronic lymphocytic leukemia and various lymphomas, the BCR signaling pathway is constitutively active, driving tumor growth and survival. Consequently, components of the BCR and its downstream signaling pathway are major therapeutic targets; drugs like BTK inhibitors (e.g., ibrutinib) and anti-CD20 monoclonal antibodies (e.g., rituximab) are widely used to treat these cancers and certain autoimmune disorders. The phrase "and other adaptive immune components" suggests a broader category including T cell receptors and MHC molecules, but the BCR remains the central therapeutic focal point in this context.

Other names

B-cell antigen receptorSurface immunoglobulin complexBCR complexAdaptive immune components

Inhibition of downstream signaling kinases (e.g., BTK, SYK, PI3K) or direct depletion of B cells via monoclonal antibodies targeting surface components.